Alnylam Pharmaceuticals (ALNY) Enterprise Value (2009 - 2026)

Alnylam Pharmaceuticals has reported Enterprise Value for 18 years, with the latest figure at -$3.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 193.05% year-over-year to -$3.0 billion; the trailing twelve-month figure through Mar 2026 stood at -$3.0 billion (down 193.05% YoY), and the FY2025 full-year result was -$2.9 billion, down 197.75% from the prior year.
• Enterprise Value for Q1 2026 stood at -$3.0 billion, down from -$2.9 billion in the prior quarter.
• The five-year high for Enterprise Value was -$685.1 million in Q2 2023, with the low at -$3.0 billion in Q1 2026.
• Historically, Enterprise Value has averaged -$2.0 billion across 5 years, with a median of -$2.2 billion in 2022.
• Annual changes were most pronounced in 2023 — Enterprise Value jumped 67.06% — and 2024, when it slumped 281.69%.
• Alnylam Pharmaceuticals' Enterprise Value stood at -$896.7 million in 2022, then tumbled by 170.8% to -$2.4 billion in 2023, then surged by 59.77% to -$976.8 million in 2024, then sank by 197.75% to -$2.9 billion in 2025, then slipped by 3.46% to -$3.0 billion in 2026.
• The last three Enterprise Value figures came in at -$3.0 billion (Q1 2026), -$2.9 billion (Q4 2025), and -$2.7 billion (Q3 2025), per Business Quant data.